Bayer

Graphic image of an arrow nailing the bullseye of a target

AbCellera tops ‘most aggressive’ hopes, putting rivals on notice

AbCellera saw phase 2 results “beyond even the most aggressive upside scenario” that its CEO had considered, sending shares up 30% in pre-market trading.

Nick Paul Taylor Aug 10, 2026 8:24am

Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Perrigo CEO ousted over ‘personal conduct’—Chutes & Ladders

Jun 12, 2026 8:30am

Bayer scraps ph.1-stage hypertension, neuropathic pain drugs

May 12, 2026 5:07am

illustration of two people shaking hands for a merger or acquisitions deal

Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect

May 6, 2026 7:20am

Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders

Apr 3, 2026 8:30am

Oryon shines out of stealth with $21M to fight Parkinson's

Mar 23, 2026 5:00am